Category: news

August 16, 2017 Off

Novo Nordisk trial shows superior glucose control and weight loss with semaglutide compared to dulaglutide

By Dino Mustafić

Novo Nordisk’s SUSTAIN 7 trial results, announced on Wednesday, showed that treating people with type 2 diabetes with once-weekly semaglutide reduced HbA1c and body weight compared to treatment with dulaglutide. The trial tested the 0.5 mg semaglutide compared with 0.75 dulaglutide, and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin.

Akers Biosciences revenues, gross profit up 10%, overhead lowered 10%
August 15, 2017 Off

Akers Biosciences revenues, gross profit up 10%, overhead lowered 10%

By Dino Mustafić

Akers Biosciences has announced the results for the first half 2017 in which it posted gross profit to be up 10% to $1,342,160, compared to the same period previous year, $1,217,634. As the total revenues moved up 10% for first 6 months of 2017 which were $1,865,112, compared to the 2016’s first half of $1,694,510, Akers Biosciences’s loss before income tax was reduced by 20% to $2,051,918, from first half in 2016, $2,517,861.

CellAct, Mundipharma in $250M cancer drug deal
August 15, 2017 Off

CellAct, Mundipharma in $250M cancer drug deal

By Dino Mustafić

CellAct Pharma, a virtual German company, has signed a more than $250 million deal with Mundipharma for further development and commercialization of CAP7.1, a prodrug etoposide that has shown efficacy in phase 2 studies in patients with biliary tract cancers. 

FDA grants priority review designation to Gilead Sciences’s HIV drug
August 11, 2017 Off

FDA grants priority review designation to Gilead Sciences’s HIV drug

By Dino Mustafić

The U.S. Food and Drug Administration (FDA) has granted priority review for the company’s New Drug Application (NDA) for Gilead Sciences’s investigational, fixed-dose combination of bictegravir (50mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF), a dual-NRTI backbone, for the treatment of HIV-1 infection.

Vifor Pharma with strong first half financial results
August 8, 2017 Off

Vifor Pharma with strong first half financial results

By Dino Mustafić

Vifor Pharma has posted strong net sales in the first half of 2017, driven by its three medium-term strategic growth drivers. It had net net profit after minorities of CHF1,094 M, ($1,124M)in the first half, compared to the same period last year of CHF158.9.